All In Biotech

Drug Trial Radar · NCT05583526

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 607 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

607

Actual

Start

Dec 1, 2022

Primary completion

Feb 5, 2026

Study completion Feb 5, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Conditions

  • Stable Nonsegmental Vitiligo
  • Active Nonsegmental Vitiligo

Interventions

  • RitlecitinibDrug

    50 mg capsule

  • PlaceboDrug

    Matching capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and T-VASI50 at Week 52Time frame: Week 52
  2. Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52Time frame: Week 52
  3. Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs), leading to discontinuation, and clinically significant laboratory abnormalitiesTime frame: Baseline through Week 52

Locations

115 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham Faculty Office Towers (Regulatory

    Birmingham, Alabama

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • Marvel Clinical Research

    Huntington Beach, California

  • Wallace Medical Group, Inc

    Los Angeles, California

  • Audiology

    Washington D.C., District of Columbia

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Center for Dermatology and Dermatologic Surgery

    Washington D.C., District of Columbia

  • Encore Medical Research of Boynton Beach

    Boynton Beach, Florida

  • Skin Care Research

    Hollywood, Florida

  • Clever Medical Research

    Miami, Florida

  • Ziaderm Research LLC

    North Miami Beach, Florida

  • Olympian Clinical Research

    St. Petersburg, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Advanced Medical Research, PC.

    Sandy Springs, Georgia

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Velocity Clinical Research at The Dermatology Clinic, Baton Rouge

    Baton Rouge, Louisiana

  • DelRicht Research

    Baton Rouge, Louisiana

  • The NeuroMedical Center (XRay)

    Baton Rouge, Louisiana

  • DelRicht Research

    New Orleans, Louisiana

  • Prairieville Family Hospital (XRay)

    Prairieville, Louisiana

  • Visage Dermatology and Aesthetic Center

    Bowie, Maryland

  • Lawrence J Green, MD LLC

    Rockville, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Hamzavi Dermatology - Canton

    Canton, Michigan

  • Skin Specialists, PC

    Omaha, Nebraska

  • University of New Mexico Health Sciences Center

    Albuquerque, New Mexico

  • SUNY Downstate Health Sciences University

    Brooklyn, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina

  • Clinical & Translational Research Center (CTRC)

    Chapel Hill, North Carolina

  • Accellacare - Wilmington

    Wilmington, North Carolina

  • Accellacare

    Wilmington, North Carolina

  • PMG Research of Wilmington, LLC

    Wilmington, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Remington Davis Clinical Research

    Columbus, Ohio

  • Remington-Davis, Inc

    Columbus, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • Bellaire Dermatology Associates

    Bellaire, Texas

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.